Vera TherapeuticsVERA
Recorded

Vera Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Vamil DivanBiopharmaceuticals Analyst

Okay, I think we are ready to get started here. Thanks again, everyone, for joining us at this year's Guggenheim Healthcare Innovation Conference. I am Vamil Divan, one of the biopharma analysts here at Guggenheim. Next up in this room, very pleased to have the Vera Therapeutics team join us. Next to me, we have Marshall Fordyce, who is the CEO of the company, Rob Brenner next to him, the CMO, and Matt Skelton, CCO, at the end of the line here. Thanks so much again for joining us. Obviously, a very eventful 12 months you guys have had since our conference last year, getting TRUTAKNA on the market, and obviously a lot of great data generation along the way.

Vamil DivanBiopharmaceuticals Analyst

Maybe, Marshall, I will just turn to you if you want to share the highlights that you guys reported last Thursday, just the highlights and what you are highlighting from the first or partial quarter on the market for TRUTAKNA.

Marshall FordyceCEO

Great. Well, thanks so much, Vamil, for hosting us here, and last night for dinner. We have had a great day with investors and hope to share our enthusiasm for bringing TRUTAKNA to patients and appreciate how many patients out there could benefit from it, how strong the launch looks in these early days. You said Matt is at the end of the line. He is at the front line. He is the Chief Commercial Officer. Really eventful year for us, and I want to provide a few highlights and happy to go right into Q&A. We at Vera are now at an inflection point with our first approved drug, and we just reported Q3 earnings last week, giving an indication of the strength of the TRUTAKNA launch in IgA nephropathy in the U.S. That is the beginning of our beachhead as a commercial entity.

Marshall FordyceCEO

We reported 700 Patient Start Forms, so an indicator of demand. That stacks up very well in terms of any renal launch, and happy to share how that looks. We see TRUTAKNA as a new foundational therapy for patients with IgAN. We think as a class, the B-cell modulator class is likely to become the new standard of care over time. We got to witness that at the ASN meeting just a few weeks ago in Denver. That is the American Society of Nephrology, the major kidney conference every year. We were able to have a presence at the opening plenary session with the presentation of our final phase III efficacy analysis. That was then published in the New England Journal of Medicine.

Marshall FordyceCEO

We were accompanied by the sibeprenlimab phase III data, which was in a similar ballpark. I think most nephrologists got the sense that the B-cell modulator class is changing the landscape and the future for these patients. So, launch looks strong in the early days. This category looks very large. I think by most estimates, from a financial point of view, the opportunity for the B-cell modulator class in the U.S. and IgAN alone looks to be closer to $20 billion as opposed to $10 billion. We and sibeprenlimab are the only current drugs on the market. We expect a third by the end of the year. So, three players in a $10 billion-$20 billion market is a fabulous opportunity for our business. Beyond that, we will be expanding into new geographic areas.

Marshall FordyceCEO

We did share that we have aligned with European regulators with our current dataset in IgAN, and we will be filing in Europe in the first quarter of next year. We are making similar progress in Japan. The first bit of expansion that you will see from us in the coming time will be geographic. Beyond that, there is indication expansion, and we showed for the first time atacicept data in patients with membranous nephropathy, which is another autoantibody-driven glomerular disease. We showed reduction in the autoantibody PLA2R. We showed a reduction in proteinuria, and internally, we are setting ourselves up for the next trial in MN. Again, that is just kind of the beginning. Outside of nephrology, we see opportunity in rheumatology, neurology, and dermatology as well.

Marshall FordyceCEO

We hope this is just the beginning of what we see as an enormous opportunity for us to serve the patients we hope to serve.

Vamil DivanBiopharmaceuticals Analyst

Great. It is a great overview. Obviously, a lot going on there. Maybe we will start with the news from last week and the sort of initial commercial uptake, and I will turn to Matt for this to kind of get your perspectives. Obviously, 700 new Patient Start Forms approximately in the first 17 weeks, a great number. Maybe you can share a little bit more of sort of the sense on the ground, sort of the dynamics as your sales force is talking to doctors, the interest in how they are deciding to start this product.

Matt SkeltonChief Commercial Officer

Sure. Happy to provide a little more color there. Well, we're really pleased where we are and what we reported last week. Importantly, our reps are getting good access to the key prescribers. We're spending a lot of time with the higher decile physicians in the space. The message is being received very well. We're very confident the product profile of TRUTAKNA, and that's generating the demand we've seen so far with the 700 Patient Start Forms. At this point in time, launch is going exceedingly well.

Vamil DivanBiopharmaceuticals Analyst

That's great. Maybe you can talk a little bit about sort of the breadth that you're seeing right now in terms of where the access is coming from, where the scripts are coming from, and then kind of your plans over the next few quarters to- Sure.

Matt SkeltonChief Commercial Officer

Yeah. And I shared this on the call last week, is we're getting a good mix from the community. We're getting a good mix from academic centers or thought leaders. We're largely drawing from the prevalent pool of patients. Think about it almost as that placebo arm of our trial. Those are the patients that are going on TRUTAKNA, right? They've been diagnosed for a while. They're on the backbone of IgA or IgAN therapies, ACEs, ARBs, SGLT2s. Some of them have maybe been through a round of TARPEYO. Those are really good TRUTAKNA patients. Their lab values aren't where the doc wants them to be, and with the strength of the TRUTAKNA profile, that's an attractive patient for a nephrologist to put on TRUTAKNA.

Marshall FordyceCEO

I would add that it's early days, right? So this is a really early time in a large market. When you do an apples-to-apples comparison of TRUTAKNA and sibeprenlimab at 17 weeks into the launch, we're at 700 Patient Start Forms. They were at roughly 1,000. That's a fantastic kind of neck and neck. Both programs are growing. This really speaks to a large market. We track everything internally. We're watching and learning that market extremely closely. On the other hand, the potential, we're still in the single digits in terms of the number of patients who could benefit from TRUTAKNA. So a pattern we see now is likely to change in a quarter or two. I think a really important data point is our sales force is rarely in a competitive sales position with another company. There's just so much opportunity, so many patients.

Marshall FordyceCEO

If you try to quantify that, we are conservative in our estimate of the number of patients who could benefit in the U.S. It is about 160,000 Americans have biopsy-proven IgAN. That is likely to be a gross underestimate because diagnoses are, that rate is relatively low. But with that as a beginning number, which patients are you worried about progressing? If you look at our own trials or the trials of others in the space, the average age is 40 years old and the average GFR is 60. If you follow them on placebo, they are on their way to dialysis by 50 years old, so within 10 years. You just have to look at the data. The urgency to treat is very evident in the data that we have shown. We are actively out there making sure that we communicate about the urgency to treat, the profile of TRUTAKNA.

Marshall FordyceCEO

That takes work. It is great that we are not alone, by the way. It is great that there is more than one voice creating that market. We see that really every day, and I think that is an important thing to appreciate. The size of the market, and we are just scratching the surface. Even then, you are looking at some trends showing the largest, most successful nephrology drug launches that we have ever seen, even just within the first few quarters. I think that is the main message we want to convey.

Vamil DivanBiopharmaceuticals Analyst

Yeah, no, I completely agree with you, and I think it is just the beginning of this huge opportunity for you and a couple other companies. We still get the great question from investors. I have to ask, as you think about the competitive landscape here, again, sibi on the market now, povetacicept maybe getting approved later this month, how you see the, again, in the context of it, you build this market and there is room for many winners. How do you see the differentiation points for TRUTAKNA against the competitors?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day